STOCK TITAN

BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces that Advanced Cell Diagnostics (ACD) has reached a milestone of over 10,000 peer-reviewed publications utilizing RNAscope™ ISH technology, solidifying its leadership in spatial biology applications. The increasing global customer awareness and market adoption signify ACD's significant impact in enabling ground-breaking biologic discoveries and therapeutic advancements.
Positive
  • None.
Negative
  • None.

The milestone achieved by Advanced Cell Diagnostics (ACD), a subsidiary of Bio-Techne Corporation, indicates a robust validation of the RNAscope™ ISH technology within the scientific community. The fact that over 50% of the 10,000 peer-reviewed publications have been released in the past three years suggests a rapid acceleration in the technology's adoption. This could signal an increased confidence in spatial biology's role in advancing therapeutic and diagnostic development, potentially leading to growth in Bio-Techne's market share and an enhanced reputation among biopharma and academic circles.

From an investment standpoint, the widespread adoption and reference in publications can be seen as an indirect indicator of the technology's commercial viability. As RNAscope™ ISH is used more extensively in research, there is a greater likelihood of it becoming standard in certain protocols, which could lead to recurring revenue streams for Bio-Techne. Additionally, the technology's application in diverse fields such as cancer, neuroscience, immunology and more, diversifies the potential customer base, thereby reducing market risks.

The announcement by Bio-Techne Corporation highlights the increasing market penetration of RNAscope™ ISH technology, which could be a positive indicator for the company's financial future. The significant number of peer-reviewed publications serves as a proxy for the technology's acceptance and could correlate with increased sales and revenue. Investors should note the potential for this technology to drive long-term revenue growth, especially as it becomes a staple in spatial biology research.

However, it is important to assess the competitive landscape and the potential for other technologies to disrupt the market. While current adoption rates are impressive, the life sciences sector is rapidly evolving and continuous innovation is necessary to maintain market leadership. The impact on Bio-Techne's stock will depend on the company's ability to capitalize on this adoption through effective commercial strategies and to sustain its innovation pipeline in the face of competition.

The spatial biology market is experiencing a surge in interest and Bio-Techne's announcement positions RNAscope™ ISH as a leading technology in this field. The broad portfolio of unique ISH probes offered by ACD suggests that Bio-Techne has successfully tapped into the growing demand for high-resolution, sensitive diagnostics and research tools. This could attract more partnerships and collaborations, potentially opening new revenue channels.

It's also worth considering the strategic implications of such a milestone. The vast number of publications not only serves as a marketing tool, enhancing brand visibility and credibility but also may influence procurement decisions within research institutions and biopharma companies. As the technology becomes more embedded in scientific research, it can lead to a stronger moat around Bio-Techne's business and possibly to pricing power over its offerings.

Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone

MINNEAPOLIS, April 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope ISH technology. Over 50% of these publications were released in the past 3 years, as increasing global customer awareness and expanded market adoption solidify ACD's leadership in spatial biology applications.

As a pioneer in spatial biology, Bio-Techne's broad portfolio of over 50,000 unique RNAscope ISH probes across over 400 species enables its biopharma and academic customers to reveal ground-breaking biologic discoveries, accelerate the development of next generation therapeutics, and deliver life-changing diagnostics. Representing the most referenced spatial biology technology in the industry for RNA biomarkers, RNAscope offers best-in-class single-molecule sensitivity with unrivaled specificity at subcellular resolution. This landmark portfolio of 10,000 scientific publications encompasses applications in cancer and neuroscience, as well as additional areas of research including immunology, infectious disease, cell and gene therapy, and regenerative medicine.

"We are thrilled to celebrate the achievement of over 10,000 publications referencing RNAscope ISH technology," said Matt McManus, President of Bio-Techne's Diagnostics & Genomics Segment. "We are honored by the trust the scientific community has placed in RNAscope to uncover new spatial insights and enable significant breakthroughs across a wide range of diseases."

About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: FacebookLinkedInTwitter or YouTube.

Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
David.clair@bio-techne.com

Bio-Techne Logo (PRNewsfoto/Bio-Techne Corporation)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-surpasses-10-000-peer-reviewed-publications-citing-rnascope-technology-302109757.html

SOURCE Bio-Techne Corporation

FAQ

How many peer-reviewed publications reference the use of RNAscope™ ISH technology?

Over 10,000 peer-reviewed publications reference the use of RNAscope™ ISH technology.

What percentage of the publications were released in the past 3 years?

Over 50% of the publications were released in the past 3 years.

What does RNAscope™ ISH technology offer in terms of sensitivity and specificity?

RNAscope™ ISH technology offers best-in-class single-molecule sensitivity with unrivaled specificity at subcellular resolution.

In which areas of research have the applications of RNAscope™ ISH technology been prominent?

The applications of RNAscope™ ISH technology have been prominent in cancer, neuroscience, immunology, infectious disease, cell and gene therapy, and regenerative medicine.

Who is the President of Bio-Techne's Diagnostics & Genomics Segment?

Matt McManus is the President of Bio-Techne's Diagnostics & Genomics Segment.

Bio-Techne Corporation

NASDAQ:TECH

TECH Rankings

TECH Latest News

TECH Stock Data

12.67B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.